Table 2. Frequency of leukocyte populations in bronchoalveolar lavage fluid (BALF) at day 7 post infection.
| Immune cell population | Mock/Mock | Mock/CA04 | IM αGC/CA04 | IN αGC/CA04 |
|---|---|---|---|---|
| CD1d tetramer+ NKT cells (of CD3+) | 0.08 ± 0.01 | 0.12 ± 0.01 | 0.49 ± 0.27 | 0.07 ± 0.03 |
| CD8α+ (of CD3+) | 81.10 ± 1.00 | 85.60 ± 1.31 | 84.03 ± 4.40 | 84.33 ± 1.17 |
| CD4+ (of CD3+) | 4.63 ± 0.09 | 2.23 ± 0.66 | 2.62 ± 0.53 | 3.85 ± 1.87 |
| CD4+CD8α+ (of CD3+) | 9.30 ± 0.69 | 6.29 ± 0.91 | 8.99 ± 2.99 | 7.22 ± 1.22 |
| CD3-CD8α+ NK cells (of lymphocytes) | 5.67 ± 0.84 | 7.47 ± 2.51 | 7.54 ± 1.58 | 8.34 ± 2.33 |
| Granulocytes (FSChi SSChi of live) | 72.4 ± 13.8 | 82.8 ± 5.52 | 78.9 ± 10.21 | 77.9 ± 5.21 |
Values represent mean ± SEM for lymphocyte-sized single cells and cell population indicated in parenthesis. No significant difference (p > 0.05) was detected between treatments for any of the immune cell populations tested when analyzed by the Kruskal-Wallis test. Mock treated and mock challenged (Mock/Mock); mock treated and CA04 challenged (Mock/CA04); 100 μg/kg α-GalCer administered i.m. (IM αGC/CA04) or i.n. (IN αGC/CA04).